成立于1998年,知名阿膠品牌,以藥業/酒業為主導,集研發/生產/經營/投資/管理于一體的綜合性集團公司,產品涵蓋了中西藥制劑/生物制藥/原料藥/保健食品等品類
1998年成立的輔仁藥業集團,是一家以藥業、酒業為主導,集研發、生產、經營、投資、管理于一體的綜合性集團公司。集(ji)(ji)團囊括河(he)南(nan)輔(fu)仁(ren)(ren)(ren)堂(tang)制(zhi)藥(yao)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)、河(he)南(nan)輔(fu)仁(ren)(ren)(ren)懷慶堂(tang)制(zhi)藥(yao)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)、開(kai)封制(zhi)藥(yao)(集(ji)(ji)團)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)、開(kai)封豫港制(zhi)藥(yao)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)、開(kai)藥(yao)集(ji)(ji)團(開(kai)魯(lu))制(zhi)藥(yao)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)、河(he)南(nan)同(tong)源制(zhi)藥(yao)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)、輔(fu)仁(ren)(ren)(ren)醫藥(yao)科技開(kai)發(fa)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)、輔(fu)仁(ren)(ren)(ren)藥(yao)業集(ji)(ji)團醫藥(yao)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)、輔(fu)仁(ren)(ren)(ren)藥(yao)業集(ji)(ji)團熙德隆腫(zhong)瘤藥(yao)品有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)、北京(jing)遠策藥(yao)業有(you)(you)限(xian)(xian)責任(ren)公(gong)(gong)司(si)(si)(si)、北京(jing)輔(fu)仁(ren)(ren)(ren)瑞輝生物(wu)(wu)醫藥(yao)研究院、上(shang)海輔(fu)仁(ren)(ren)(ren)醫藥(yao)研發(fa)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)、鄭州遠策生物(wu)(wu)制(zhi)藥(yao)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)、河(he)南(nan)省宋(song)河(he)酒業股(gu)份(fen)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)及上(shang)市公(gong)(gong)司(si)(si)(si)輔(fu)仁(ren)(ren)(ren)藥(yao)業集(ji)(ji)團制(zhi)藥(yao)股(gu)份(fen)有(you)(you)限(xian)(xian)公(gong)(gong)司(si)(si)(si)等(deng)多家全資、控股(gu)子(zi)公(gong)(gong)司(si)(si)(si)。
集團產(chan)(chan)品涵蓋了(le)中西藥(yao)制(zhi)劑、生(sheng)物制(zhi)藥(yao)、原料藥(yao)、保健(jian)食品等(deng)多個門類。2006年,隨著河(he)南輔(fu)(fu)仁(ren)堂(tang)制(zhi)藥(yao)有(you)限(xian)公司成功實現上市,資(zi)本的(de)力量不僅把(ba)輔(fu)(fu)仁(ren)推向一個飛速發(fa)展時期,其(qi)行業地位亦逐步提升。2017年12月(yue)29日,輔(fu)(fu)仁(ren)藥(yao)業重大資(zi)產(chan)(chan)重組成功,把(ba)集團優質資(zi)產(chan)(chan)——開封制(zhi)藥(yao)(集團)有(you)限(xian)公司置入輔(fu)(fu)仁(ren)藥(yao)業,使輔(fu)(fu)仁(ren)藥(yao)業跨(kua)入一個新(xin)的(de)發(fa)展階(jie)段。
“品(pin)種(zhong)(zhong)(zhong)為核心(xin),并(bing)購(gou)為主線”的早(zao)期發展戰略讓輔(fu)仁藥(yao)業集團的產能(neng)和產品(pin)線在很短(duan)時間內飛速發展。迄(qi)今,輔(fu)仁藥(yao)業集團已擁(yong)有(you)水針(zhen)劑(ji)、凍干粉(fen)針(zhen)劑(ji)、口(kou)服固(gu)體(ti)制(zhi)劑(ji)等20多個劑(ji)型(xing),1000余個品(pin)種(zhong)(zhong)(zhong);制(zhi)劑(ji)綜合產能(neng)位居全國(guo)(guo)制(zhi)藥(yao)行業前茅。2017新版(ban)醫保目錄(lu)輔(fu)仁藥(yao)業集團共(gong)(gong)入選578個品(pin)種(zhong)(zhong)(zhong),較2009版(ban)目錄(lu)增(zeng)加(jia)品(pin)種(zhong)(zhong)(zhong)165個,增(zeng)幅39.95%,其(qi)中(zhong)甲(jia)類入選364個,增(zeng)幅42.754%,乙(yi)類入選214個,增(zeng)幅35.44%。在國(guo)(guo)家(jia)(jia)衛健委正(zheng)式發布《國(guo)(guo)家(jia)(jia)基本(ben)藥(yao)物目錄(lu)(2018年版(ban))》中(zhong),輔(fu)仁藥(yao)業集團共(gong)(gong)有(you)阿(a)莫西林克拉(la)維酸鉀(jia)干混懸劑(ji)、奧美拉(la)唑腸溶膠囊、注射(she)用重組(zu)人(ren)干擾素α2b等262個品(pin)規榜上有(you)名(ming),較2012版(ban)目錄(lu)增(zeng)加(jia)75個,增(zeng)幅40.11%,成為全國(guo)(guo)入選品(pin)種(zhong)(zhong)(zhong)較多的制(zhi)藥(yao)企(qi)業之一。
輔仁藥業集團一(yi)(yi)直遵循“濟(ji)世(shi)藥為(wei)輔、惠(hui)(hui)民志在仁”的(de)企業理念,始終貫(guan)徹“產量讓(rang)(rang)位于質(zhi)量、成本讓(rang)(rang)位于質(zhi)量”的(de)質(zhi)量管(guan)理方針,本著“和(he)而不(bu)同、化繁為(wei)簡(jian)、務(wu)實(shi)創新(xin)、濟(ji)世(shi)惠(hui)(hui)民”的(de)企業價值觀,把“做(zuo)一(yi)(yi)家實(shi)體型、科(ke)技(ji)型、國(guo)際型企業”作(zuo)為(wei)自(zi)己的(de)企業定位,兼(jian)容(rong)并(bing)蓄,尊重規律,踐行規則(ze)。
在企業并購的(de)同時,輔(fu)仁藥(yao)業集(ji)團(tuan)投入巨資加強企業創(chuang)(chuang)新(xin)(xin)平臺(tai)(tai)建設,戰略性布局鄭州(zhou)技術(shu)研(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)和(he)國際(ji)化(hua)合作及(ji)產(chan)業化(hua)服務(wu)平臺(tai)(tai)、北京創(chuang)(chuang)新(xin)(xin)研(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)平臺(tai)(tai)、上海(hai)醫(yi)藥(yao)研(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)創(chuang)(chuang)新(xin)(xin)國際(ji)合作平臺(tai)(tai)、美國新(xin)(xin)澤西、費城研(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)平臺(tai)(tai)四大(da)研(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)創(chuang)(chuang)新(xin)(xin)平臺(tai)(tai),以(yi)及(ji)中(zhong)醫(yi)藥(yao)大(da)數據及(ji)人(ren)工智能中(zhong)醫(yi)研(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)平臺(tai)(tai),更將在小(xiao)分子化(hua)學藥(yao)、大(da)分子生物藥(yao)研(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)和(he)中(zhong)醫(yi)藥(yao)傳承(cheng)創(chuang)(chuang)新(xin)(xin)方(fang)向同時發(fa)(fa)(fa)(fa)力,開辟以(yi)研(yan)(yan)(yan)(yan)發(fa)(fa)(fa)(fa)驅動創(chuang)(chuang)新(xin)(xin)的(de)發(fa)(fa)(fa)(fa)展(zhan)新(xin)(xin)路徑。
目(mu)前,輔(fu)(fu)仁藥業集(ji)團支持創新研(yan)發面(mian)積達11.3萬平方米,研(yan)發創新隊伍(wu)近(jin)1500人(ren)。同時(shi),秉承“中國市(shi)場、輔(fu)(fu)仁平臺、全球資源”的發展策略,輔(fu)(fu)仁藥業集(ji)團實(shi)現了從(cong)“百姓藥、輔(fu)(fu)仁造(zao)(zao)”到(dao)“創新藥、輔(fu)(fu)仁造(zao)(zao)”的可持續(xu)發展跨越,為客戶及整個社會創造(zao)(zao)價值,健康(kang)中國,服務(wu)世(shi)界。